AstraZeneca, working with genome pioneer Craig Venter, is launching a massive gene hunt in the most comprehensive bet yet by a pharmaceutical firm on the potential of genetic variations to unlock routes to new medicines.
The initiative, announced on Friday, involves sequencing up to 2 million human genomes – the complete set of genetic code that acts as the software of life – including 500,000 DNA samples collected by AstraZeneca in global clinical trials.
Source: Reuters
Filed Under: Drug Discovery
